Why the study?
More precise laboratory prediction of cardiovascular risk requires quantification of atherogenic lipoproteins, and angiopoietin-like proteins 3, 4, and 8 have recently emerged as regulators of lipoprotein metabolism and potential targets.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
ANGPTLs may refine CVD risk prediction beyond lipoproteins; leaves open clinical adoption pending higher-level evidence.
Scientists have been trying to find the best parameter for laboratory assessment of the risk of cardiovascular diseases (CVD) for decades. Initially, the results of many studies indicated that the analysis of the lipid profile was sufficient to evaluate the risk of CVD. Further studies revealed that more precise laboratory prediction of cardiovascular risk requires quantification of atherogenic lipoproteins. Recently, angiopoietin-like proteins 3, 4 and 8 (ANGPTLs) have been described as important regulators of plasma lipoprotein metabolism and triglyceride homeostasis. Mutations in ANGPTL3 leading to loss of its function have been linked to decreased risk of CVD in humans. Among potential new targets for the management of dyslipidemia, ANGPTL3 may become a considerably promising one.
No takes yet. Share an insight, caveat, or question.
Murawska et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: